Pulmotect
Houston, US · 2 known investors
Pulmotect develops PUL-042, a clinical-stage inhaled therapeutic that stimulates the innate immune system in the lungs to protect against viral, bacterial, and fungal pathogens. The drug is being studied for preventing respiratory complications such as pneumonia and for improving outcomes in immunocompromised cancer patients, as well as populations with COPD, asthma, and seasonal infections.
Founders & leadership
CB
Colin BroomExecutive Officer, Director
MW
Mark WorschehDirector
LL
Leo Linbeck IIIDirector
KS
Kumar SrinivasanDirector
AV
Atul VaradhacharyDirector
LE
Leo E. LinbeckDirector
BS
Brenton ScottDirector
MH
Magnus HookDirector
BG
Bruce GivenDirector
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$10.3MraisedSep 2024 · 15 investors · BiotechnologyRule 506(b)
▶$10.3MraisedSep 2024 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kumar SrinivasanDirector
- Magnus HookDirector
- Atul VaradhacharyDirector
- Colin BroomExecutive Officer, Director
- Bruce GivenDirector
- Leo E. LinbeckDirector
- Brenton ScottDirector
- Amount sold
- $10.3M
- Proceeds to insiders
- $726.8K
- First sale
- Aug 2024
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
▶$3.7MraisedJan 2024 · 11 investors · BiotechnologyRule 506(b)
▶$3.7MraisedJan 2024 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kumar SrinivasanDirector
- Brenton ScottExecutive Officer
- Atul VaradhacharyDirector
- Magnus HookDirector
- Colin BroomExecutive Officer, Director
- Bruce GivenDirector
- Leo E. Linbeck IIIDirector
- Amount sold
- $3.7M
- Finders' fees
- $7.5K
- Proceeds to insiders
- $1.2M
- Placement agents
- 16 Points LLC
- First sale
- Jan 2022
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
▶$1.5MraisedSep 2023 · 2 investors · BiotechnologyRule 506(b)
▶$1.5MraisedSep 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bruce GivenDirector
- William NossExecutive Officer
- James GamettDirector
- Colin BroomExecutive Officer, Director
- Atul VaradhacharyDirector
- Brenton ScottExecutive Officer
- Kumar SrinivasanDirector
- Leo E. Linbeck IIIDirector
- Magnus HookDirector
- Amount sold
- $1.5M
- First sale
- May 2023
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
▶$3.5MraisedMar 2021 · 21 investors · BiotechnologyRule 506(b)
▶$3.5MraisedMar 2021 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brenton ScottExecutive Officer
- Colin BroomExecutive Officer, Director
- Kumar SrinivasanDirector
- Mark BenedykDirector
- Atul VaradhacharyDirector
- Bruce GivenDirector
- Leo Linbeck IIIDirector
- Magnus HookDirector
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- Sales commissions
- $17.6K
- Placement agents
- 16 Points LLC
- First sale
- Mar 2021
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
▶$6.1MraisedFeb 2020 · 22 investors · BiotechnologyRule 506(b)
▶$6.1MraisedFeb 2020 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brenton ScottExecutive Officer
- Colin BroomExecutive Officer, Director
- Kumar SrinivasanDirector
- Bruce GivenDirector
- Mark BenedykDirector
- Leo Linbeck IIIDirector
- Magnus HookDirector
- Atul VaradhacharyDirector
- Amount sold
- $6.1M
- First sale
- Feb 2018
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
▶$1.8MraisedMay 2016 · 5 investors · BiotechnologyRule 506(b)
▶$1.8MraisedMay 2016 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brenton ScottExecutive Officer, Promoter
- Mark WorschehDirector
- Bruce GivenDirector
- Magnus HookDirector
- Atul VaradhacharyDirector
- Leo Linbeck IIIDirector
- Offering amount
- $2.5M
- Amount sold
- $1.8M
- First sale
- Apr 2016
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.